ADHD

Gambling

Opioid Related Disorders

Alcohol Abuse

Amphetamine Related Disorders

Substance Use Disorder

Addiction & Substance Use

Disaster Psychiatry

Panic Disorder

Trauma And Violence

Traumatic Stress Disorders

Anxiety & Stress Disorders

Mania

Bipolar Disorder

COVID-19

Cannabis

Case Discussions

Child & Adolescent Psychiatry

Climate Change

Comorbidity

Compulsive Disorders

Cultural Psychiatry

Digital Therapeutics

Diversity, Equity, Inclusion

Drug Watch

Eating Disorders

Emergency Psychiatry

Ethics

Munchausen Syndrome

Sexual Offenses

Forensic Psychiatry

Geriatric Psychiatry

Integrative Psychiatry

Major Depressive Disorder

Mental Health Awareness Month

Mood Disorders

Cognitive Disorders

Dementia

Alzheimer Disease

Autism

Neuropsychiatry

PTSD

Compulsive Personality Disorder

Dependent Personality Disorder

Dissociative Identity Disorder

Histrionic Personality Disorder

Schizoid Personality Disorder

Antisocial Personality Disorder

Borderline Personality

Personality Disorders

Postpartum Depression

Psychedelics

Psychopharmacology

Delirium

Metabolic Disorders

Somatoform Disorder

Psychosomatics

Cognitive Behavioral Therapy

Psychotherapy

Paranoid Schizophrenia

Psychotic Affective Disorders

Schizoaffective

Schizophrenia Psychotic Features

Schizotypal Personality Disorder

Catatonic Schizophrenia

Schizophrenia/Psychosis

Nocturnal Paroxysmal Dystonia

Sleep Deprivation

Sleep Wake Transition

Circadian Rhythm Sleep Disorders

Sleep Disorders

Pervasive Developmental Disorder

Gender Issues

Military Mental Health

Special Populations

Suicide

Tardive Dyskinesia

Technology & Psychiatry

Transcranial Magnetic Stimulation

News

Media

Around the Practice

Between the Lines

PsychView

Expert Perspectives

Case-Based Psych Perspectives

Clinical Case Collective

Dialogues

Payer-Provider Perspective

Slideshows

Videos

Viewpoints

Conferences

Conference Coverage

Conference Listing

Publication

Psychiatric Times

Job Board

CME/CE

Partners

Editorial

Resources

Clinical Consult

Clinical Scales

Interactive Tools

Partner Perspectives

Quizzes

Series

Special Reports

Subscribe

is a clinical and forensic child and family psychiatrist in Solana Beach, California. He is also the editor in chief of

Articles

What is the appropriate duration for antipsychotic use and how can you safely taper or discontinue them?

Discontinuing Antipsychotics

The lates update in lecanemab’s journey: the FDA has accepted the BLA for lecanemab-irmb subcutaneous autoinjector for weekly maintenance dosing. 

FDA Accepts Biologics License Application for Lecanemab-irmb

Are you attending Real Psychiatry this weekend? 

Don't Miss Us at Real Psychiatry!

currently serves as Chief Medical Officer for Delix Therapeutics, is a diplomate of the American Board of Psychiatry and Neurology, and retains active board certification in adult and geriatric psychiatry. 

Prior to joining Delix, Dr Koenig was vice president of Early Medical Science (Clinical Development) at Sage Therapeutics. During his time at Sage, Dr Koenig was responsible for conceptualizing, designing, and executing on Sage’s clinical-stage neuropsychiatry programs, from first-in-human to pivotal Ph2b studies. In this capacity, Dr Koenig oversaw assets within Sage’s early and mid-stage neuropsychiatry portfolio and managed a team of physicians and clinical scientists to ensure seamless execution of high-priority clinical development programs. Prior to Sage, Dr Koenig served as an associate medical director in the Alzheimer’s Disease Research Unit at Biogen.

DLX-001 is a novel neuroplastogen under development for the treatment of major depressive disorder. Learn more about the latest phase 1 data here. 